TREN Stock Price, News & Analysis

Avant Technologies (OTCQB: AVAI) and its joint venture partner Ainnova Tech have announced an enhanced patient recruitment strategy for their upcoming FDA clinical trial of the Vision AI platform, designed for early detection of diabetic retinopathy. The study will be conducted across 8-10 U.S. clinical sites, targeting approximately 1,000 multiethnic patients with diabetes.

The companies will collaborate with Fortrea, a renowned Contract Research Organization specializing in ophthalmology studies. The trial will focus on community clinics and primary care facilities rather than specialized centers to gather real-world data. This strategic approach aims to support the company's FDA 510(k) submission for Vision AI, with Ai-nova Acquisition Corp. (AAC) holding worldwide licensing rights for Ainnova's technology portfolio.

Avant Technologies (OTCQB: AVAI) announced plans to establish a new company focused on diabetes treatment expansion. This development follows their successful joint venture with Ainnova Tech through Ai-nova Acquisition Corp (AAC), which utilizes the Vision AI platform for detecting diabetic retinopathy and other diseases.

The company's Vision AI technology can identify early markers of various conditions, including diabetic retinopathy, which affects over 30% of diabetes patients. With over 500 million people globally living with diabetes, Avant aims to expand from diagnosis to treatment through potential joint ventures, partnerships, or acquisitions.

Avant Technologies (OTCQB: AVAI) has signed a non-binding letter of intent (LOI) for a business combination with Ainnova Tech, a healthcare technology company specializing in AI-powered early disease detection. The merger would integrate 100% of Ainnova's equity into the combined public company, with the final structure pending due diligence. The companies expect to announce a definitive agreement by early next quarter, subject to various approvals. This merger builds on their existing joint venture through Ai-nova Acquisition Corp., formed in late 2024. The timing aligns with their upcoming FDA pre-submission meeting in July regarding Ainnova's Vision AI platform for diabetic retinopathy detection. The merger aims to streamline technology commercialization and enhance shareholder value by combining their AI healthcare capabilities.

Avant Technologies (OTCQB: AVAI) and its partner Ainnova Tech are expanding their joint venture, Ai-nova Acquisition Corp (AAC), across Latin America following Ainnova's participation in the 2025 Healthcare Innovation Summit in Mexico City. The expansion includes commercial pilots in Chile and Dominican Republic hospitals, focusing on demonstrating cost reduction in preventive diagnostics and improved healthcare efficiency.

The pilots utilize Ainnova's Vision AI platform for real-time health risk identification, enabling specialty care referrals. The joint venture plans to deploy an automated retinal imaging device integrated with AI to screen for cardiovascular disease, type 2 diabetes, liver fibrosis, and chronic kidney disease using retinal images and basic health data.

AAC holds global licensing rights for Ainnova's technology portfolio. The companies are pursuing regulatory approvals in Brazil through MDSAP certification for ANVISA requirements, while simultaneously preparing for FDA clinical trials in the United States.